Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 2/20 | 0.48 |
| ▸ | ELANE | P08246 | 2/20 | 0.48 |
| ▸ | CTSG | P08311 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613583 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19AGTR2 | |
| SCHEMBL21874593 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19AGTR2 | |
| SCHEMBL4920606 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19AGTR2 | |
| SCHEMBL820518 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19AGTR2 | |
| SCHEMBL16857371 | 0.93 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19KMT2A | |
| SCHEMBL19234258 | 0.93 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19AGTR2 | |
| SCHEMBL19592114 | 0.93 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19AGTR2 | |
| SCHEMBL2678862 | 0.93 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19AGTR2 | |
| Hydrochloric Acid SCHEMBL5409774 | 0.92 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19AGTR2 | |
| SCHEMBL13547241 | 0.91 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015179952-A1 | A METABOLITE PANEL FOR IMPROVED SCREENING AND DIAGNOSTIC TESTING OF CYSTIC FIBROSIS | MCMASTER UNIVERSITY (CA) | 2015-12-03 | — | — | WO | claimed |
| WO-2015179952-A1 | A METABOLITE PANEL FOR IMPROVED SCREENING AND DIAGNOSTIC TESTING OF CYSTIC FIBROSIS | MCMASTER UNIVERSITY (CA) | 2015-12-03 | — | — | WO | disclosed |
| EP-1692157-B1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMA (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2573083-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8217048-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-8039623-B2 | Peptidomimetics compound; viricides; interference in life cycle og hepatitis c virus | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-18 | — | — | US | disclosed |
| EP-2361925-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20110104115-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCOROPRATED (US) | 2011-05-05 | — | — | US | disclosed |
| CN-101951766-A | Inhibitor of apoptosis-inhibiting protein | TETRALOGIC PHARMACEUTICAL CORP | 2011-01-19 | — | — | CN | disclosed |
| EP-0748331-A1 | MODIFIED OLIGONUCLEOTIDE DUPLEXES HAVING ANTICANCER ACTIVITY | EPOCH PHARMACEUTICALS, INC. (US) | 1996-12-18 | — | — | EP | disclosed |
| US-5512667-A | Trifunctional intermediates for preparing 3'-tailed oligonucleotides | DRUG ROYALTY LP1 (CA) | 1996-04-30 | — | — | US | disclosed |
| WO-1995023162-A1 | MODIFIED OLIGONUCLEOTIDE DUPLEXES HAVING ANTICANCER ACTIVITY | MICROPROBE CORPORATION (US) | 1995-08-31 | — | — | WO | disclosed |
| US-5419966-A | Solid support for synthesis of 3'-tailed oligonucleotides | MICROPROBE CORPORATION (US) | 1995-05-30 | — | — | US | disclosed |
| EP-0547142-A4 | — | MICROPROBE CORP (US) | 1995-01-18 | — | — | EP | disclosed |
| US-5280034-A | Bis-heterocyclic prostaglandin analogs | E. R. SQUIBB & SONS, INC. (US) | 1994-01-18 | — | — | US | disclosed |
| WO-1993020094-A1 | HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR QUINOLINE | ABBOTT LABORATORIES (US) | 1993-10-14 | — | — | WO | disclosed |
| EP-0547142-A1 | SOLID SUPPORT SYNTHESIS OF 3'-TAILED OLIGONUCLEOTIDES VIA A LINKING MOLECULE | EPOCH PHARMACEUTICALS, INC. (US) | 1993-06-23 | — | — | EP | disclosed |
| WO-1992003464-A1 | SOLID SUPPORT SYNTHESIS OF 3'-TAILED OLIGONUCLEOTIDES VIA A LINKING MOLECULE | MICROPROBE CORPORATION (US) | 1992-03-05 | — | — | WO | disclosed |
| US-4241076-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1980-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288116-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC7 | SMN1; SMN2 1875/4885NPC1 2535/4885RAB9A 2105/4885 |
| US-20110104115-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | SERPINB1, PRSS1, SPINT2 | SMN1; SMN2 2459/4885NPC1 447/4885RAB9A 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.